INDP

Business Context and Reporting Period

Company: Indaptus Therapeutics, Inc. (INDP)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2026
Business Overview: Indaptus is a clinical-stage biotechnology company developing a novel, multi-targeted immunotherapy (Decoy20) for unresectable or metastatic solid tumors and lymphomas. The company has discontinued enrollment in its Phase 1 Combination Study and currently has no plans to initiate new clinical trials. Management is actively evaluating strategic options, including potential investments or acquisitions ("Post-Investment Transaction").

Key Financial Metrics

Note: Share data is retroactively restated for a 1-for-28 reverse stock split effective June 27, 2025.

Material Changes vs. Prior Period

• Expense Reduction: Total operating expenses decreased by 53% ($2.4 million) compared to Q1 2025. Research and Development (R&D) expenses dropped 83% to $0.5 million, primarily due to the wind-down of the Phase 1 clinical trial and reductions in headcount and salaries.
• Cash Burn: Despite lower operating expenses, net cash used in operating activities increased to $7.0 million from $5.0 million. This was driven by a significant reduction in accounts payable ($5.2 million decrease) as the company paid down accrued liabilities from the prior year.
• Capital Structure: All outstanding Series AA and Series AAA Preferred Stock (acquired in December 2025) were converted into 111,000,000 shares of common stock during Q1 2026. Additionally, the company terminated its Securities Purchase Agreement (SEPA) with Yorkville effective March 11, 2026.
• Non-Cash Charges: The company recorded a $0.4 million expense related to the repricing of outstanding warrants to an exercise price of $1.75 per share.

Outlook, Risks, and Management Commentary

• Going Concern: The company has identified conditions that raise substantial doubt about its ability to continue as a going concern. Management believes current cash reserves ($1.5 million) are sufficient only through the second quarter of 2026.
• Capital Needs: Indaptus must raise additional capital through equity or debt financing to fund ongoing activities and strategic evaluations. Failure to secure funding may force the company to delay, limit, or eliminate research programs or cease operations.
• Strategic Pivot: With clinical trials paused, the focus has shifted to evaluating strategic transactions (M&A or investment) to create future growth opportunities.
• Management Changes: Significant executive turnover occurred recently, including the resignation of the CFO (Nir Sassi) and Chief Scientific Officer (Michael Newman), and the appointment of Yu Ding as the new CFO. Former CEO David E. Lazar also resigned.
• Risks: Key risks include the inability to raise capital, dilution to shareholders, reliance on third-party manufacturers, and the inherent uncertainties of clinical development and regulatory approval.

Investor Verification Checklist

• Liquidity Runway: Verify the timeline for the next capital raise, as cash on hand is projected to last only through Q2 2026.
• Strategic Transaction Progress: Monitor disclosures regarding the "Post-Investment Transaction" to determine if the company is pursuing an acquisition or merger to survive.
• Warrant Repricing Impact: Assess the dilution impact of the warrant exercise price reduction to $1.75 and the associated voting agreements.
• Management Stability: Evaluate the impact of recent executive departures (CEO, CFO, CSO) on the company's strategic direction and operational continuity.
• Liability Settlement: Confirm that the significant reduction in accounts payable reflects actual cash outflows and does not indicate ongoing disputes with vendors.